Literature DB >> 17225719

Association of airway hyperresponsiveness with reduced quality of life in patients with moderate to severe asthma.

Celeste Porsbjerg1, Linda Rasmussen, Hendrik Nolte, Vibeke Backer.   

Abstract

BACKGROUND: Airway hyperresponsiveness (AHR) is an indicator of poor asthma control. Asthma patients with AHR to methacholine have been shown to have a poorer quality of life compared with asthma patients without AHR, but it is not clear to what degree this is a result of more severe disease in patients with AHR.
OBJECTIVES: To describe the relationship between AHR and quality of life in asthma patients and to determine the impact of the severity of asthma on this relationship.
METHODS: Data from 691 asthma patients were analyzed to describe the relationship between the impact of AHR to methacholine (cumulative dose of methacholine required to provoke a 20% decrease in forced expiratory volume in 1 second, < or = 8 micromol) on quality of life (measured by the Asthma Quality of Life Questionnaire) of asthma patients in relation to the severity of asthma (according to the Global Initiative for Asthma guidelines).
RESULTS: Asthma patients with AHR had more severe asthma and a poorer quality of life compared with asthma patients without AHR. Furthermore, the quality of life decreased with increasing severity of asthma. However, regression analysis showed an independent association between both the presence of AHR and the severity of asthma and quality of life, as well as an interaction between the effects of these 2 factors. Finally, subgroup analysis showed that the impact of AHR on the quality of life was only clinically significant in moderate to severe asthma but not in mild asthma.
CONCLUSIONS: AHR is associated with a negative impact on the quality of life of asthma patients that is partly independent of the severity of asthma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17225719     DOI: 10.1016/S1081-1206(10)60858-7

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  7 in total

1.  Can GPCRs Be Targeted to Control Inflammation in Asthma?

Authors:  Pawan Sharma; Raymond B Penn
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  The flavonoid cyanidin blocks binding of the cytokine interleukin-17A to the IL-17RA subunit to alleviate inflammation in vivo.

Authors:  Caini Liu; Liang Zhu; Koichi Fukuda; Suidong Ouyang; Xing Chen; Chenhui Wang; Cun-Jin Zhang; Bradley Martin; Chunfang Gu; Luke Qin; Suguna Rachakonda; Mark Aronica; Jun Qin; Xiaoxia Li
Journal:  Sci Signal       Date:  2017-02-21       Impact factor: 8.192

3.  Exercise-Induced Asthma Symptoms and Nighttime Asthma: Are They Similar to AHR?

Authors:  V Backer; L M Rasmussen
Journal:  J Allergy (Cairo)       Date:  2009-11-12

4.  Eosinophil Inflammation and Hyperresponsiveness in the Airways as Phenotypes of COPD, and Usefulness of Inhaled Glucocorticosteroids.

Authors:  Hiroaki Kume; Masayuki Hojo; Naozumi Hashimoto
Journal:  Front Pharmacol       Date:  2019-07-25       Impact factor: 5.810

5.  Airway hyperresponsiveness and quality of life in Western red cedar asthmatics removed from exposure.

Authors:  Jian-Qing He; Moira Chan-Yeung; Chris Carlsten
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240

6.  YKL-40 and genetic status of CHI3L1 in a large group of asthmatics.

Authors:  Jakob W Hansen; Simon F Thomsen; Celeste Porsbjerg; Linda M Rasmussen; Lotte Harmsen; Julia S Johansen; Vibeke Backer
Journal:  Eur Clin Respir J       Date:  2015-09-16

7.  KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma.

Authors:  Katherine N Cahill; Howard R Katz; Jing Cui; Juying Lai; Shamsah Kazani; Allison Crosby-Thompson; Denise Garofalo; Mario Castro; Nizar Jarjour; Emily DiMango; Serpil Erzurum; Jennifer L Trevor; Kartik Shenoy; Vernon M Chinchilli; Michael E Wechsler; Tanya M Laidlaw; Joshua A Boyce; Elliot Israel
Journal:  N Engl J Med       Date:  2017-05-18       Impact factor: 91.245

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.